These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 34993676)
1. Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI. Tamura H; Akune Y; Hiratsuka Y; Kawasaki R; Kido A; Miyake M; Goto R; Yamada M Jpn J Ophthalmol; 2022 Jan; 66(1):19-32. PubMed ID: 34993676 [TBL] [Abstract][Full Text] [Related]
2. The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study. Tamura H; Goto R; Akune Y; Hiratsuka Y; Hiragi S; Yamada M PLoS One; 2015; 10(7):e0133628. PubMed ID: 26214804 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening. Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045 [TBL] [Abstract][Full Text] [Related]
4. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration. Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468 [TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea. Ra H; Song LD; Choi JA; Jee D PLoS One; 2018; 13(10):e0206690. PubMed ID: 30379971 [TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318 [TBL] [Abstract][Full Text] [Related]
7. Artificial Intelligence in Community-Based Diabetic Retinopathy Telemedicine Screening in Urban China: Cost-effectiveness and Cost-Utility Analyses With Real-world Data. Lin S; Ma Y; Xu Y; Lu L; He J; Zhu J; Peng Y; Yu T; Congdon N; Zou H JMIR Public Health Surveill; 2023 Feb; 9():e41624. PubMed ID: 36821353 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and cost-utility of traditional and telemedicine combined population-based age-related macular degeneration and diabetic retinopathy screening in rural and urban China. Li R; Yang Z; Zhang Y; Bai W; Du Y; Sun R; Tang J; Wang N; Liu H Lancet Reg Health West Pac; 2022 Jun; 23():100435. PubMed ID: 35355615 [TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study. Kawasaki R; Akune Y; Hiratsuka Y; Fukuhara S; Yamada M Ophthalmic Epidemiol; 2015 Feb; 22(1):4-12. PubMed ID: 25517603 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model. Cui Z; Zhou W; Chang Q; Zhang T; Wang H; Meng X; Liu Y; Yan H Front Med (Lausanne); 2021; 8():750132. PubMed ID: 34926500 [No Abstract] [Full Text] [Related]
13. Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data. Lee AY; Butt T; Chew E; Agron E; Clemons TE; Egan CA; Lee CS; Tufail A; Br J Ophthalmol; 2018 Apr; 102(4):465-472. PubMed ID: 28835423 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of combined population-based screening for multiple blindness-causing eye diseases in China: a cost-effectiveness analysis. Liu H; Li R; Zhang Y; Zhang K; Yusufu M; Liu Y; Mou D; Chen X; Tian J; Li H; Fan S; Tang J; Wang N Lancet Glob Health; 2023 Mar; 11(3):e456-e465. PubMed ID: 36702141 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model. Vottonen P; Kankaanpää E Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048 [TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Sharma S; Brown GC; Brown MM; Hollands H; Shah GK Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079 [TBL] [Abstract][Full Text] [Related]
18. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Hopley C; Salkeld G; Wang JJ; Mitchell P Br J Ophthalmol; 2004 Apr; 88(4):450-4. PubMed ID: 15031152 [TBL] [Abstract][Full Text] [Related]
19. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842 [TBL] [Abstract][Full Text] [Related]
20. Association of Choroidal Thickness with Intermediate Age-Related Macular Degeneration in a Japanese Population. Sasaki M; Ito Y; Yamasaki T; Yanagi Y; Gemmy Cheung CM; Motomura K; Kawakami S; Kinoshita T; Yuki K; Hanyuda A; Mimura M; Sawada N; Tsugane S; Tsubota K Ophthalmol Retina; 2021 Jun; 5(6):528-535. PubMed ID: 32896678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]